Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compact Tabletop Magnetic Resonance Elastography for Mapping Soft Tissue Viscoelasticity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials.

Arthritis research & therapy·2026
Same author

[Practical management of Sjögren's disease in the era of new treatment options : Current value of available outcome parameters].

Zeitschrift fur Rheumatologie·2026
Same author

Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.

Annals of the rheumatic diseases·2026
Same author

How calculating consensus change scores can go wrong: lessons from multireader imaging assessments in axial spondyloarthritis.

Annals of the rheumatic diseases·2025
Same author

Assessing age and cold ischemia effects on liver tissue viscoelastic properties: Implications for graft quality assessment with MRE during machine perfusion.

Journal of the mechanical behavior of biomedical materials·2025

Related Experiment Video

Updated: May 19, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Methotrexate: optimizing the efficacy in rheumatoid arthritis.

Jürgen Braun

    Therapeutic Advances in Musculoskeletal Disease
    |August 8, 2012
    PubMed
    Summary

    Methotrexate (MTX) is a primary drug for rheumatoid arthritis (RA) treatment. Combinations with biologics offer superior efficacy and structural damage inhibition compared to monotherapy.

    Area of Science:

    • Rheumatology
    • Pharmacology

    Background:

    • Methotrexate (MTX) has been used for rheumatoid arthritis (RA) since the 1950s.
    • It became the first-choice disease-modifying antirheumatic drug (DMARD) for RA in the 1990s.
    • DMARDs are defined by their ability to inhibit radiographic progression in RA.

    Purpose of the Study:

    • To review the role and efficacy of Methotrexate (MTX) in rheumatoid arthritis (RA) treatment.
    • To discuss various combination therapies involving MTX.
    • To compare MTX monotherapy with combination strategies, including biologics.

    Main Methods:

    • Literature review of Methotrexate (MTX) in rheumatoid arthritis (RA) treatment.
    • Analysis of clinical trial data on MTX monotherapy and combination therapies.
    • Comparison of efficacy and structural damage inhibition across different treatment regimens.
    Keywords:
    DMARDscombination therapymethotrexatemonotherapyrheumatoid arthritistherapeutic strategies

    Related Experiment Videos

    Last Updated: May 19, 2026

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
    04:50

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

    Published on: May 16, 2025

    Main Results:

    • MTX monotherapy, up to 30 mg/week, shows significant efficacy.
    • Parenteral MTX may offer benefits over oral administration.
    • Combinations like MTX + sulfasalazine + hydroxychloroquine, MTX + leflunomide, and MTX + biologics are key strategies.
    • MTX combined with biologics (anti-TNF, IL6 inhibitors, etc.) is superior to monotherapy for inhibiting structural damage.

    Conclusions:

    • Methotrexate (MTX) remains the cornerstone of RA treatment, often as the first-choice DMARD.
    • Combination therapy, particularly with biologics, significantly enhances efficacy and reduces structural damage in RA.
    • Current RA management strategies prioritize MTX in achieving patient remission.